They exclusively produce synthetic toxicity in cancerous cells through homologous recombination deficiencies (HRDs), and one of the most prominent mechanisms is via mutations in the BRCA1/2 genes present in cancer cells. This evidence concerns the gene BRCA1 and cancer.